
The Executive Director of Early Clinical Development leads the strategic planning and operational execution of clinical programs for Revolution Medicines, a biotech focused on novel RAS-targeted oncology therapies. This senior role involves designing and overseeing Phase 1 through late-stage trials, managing cross-functional teams, and driving regulatory submissions to bring transformative treatments to patients. The position offers the opportunity to shape the future of a robust pipeline while mentoring high-performing professionals in a collaborative environment. The role is based in Redwood City, California, with a hybrid work arrangement, and appeals to candidates seeking to make a meaningful impact on patients with RAS-addicted cancers within a mission-driven culture.














